KLOW peptide dosage, read strictly as research context.

The short version

There is no validated human dose for KLOW peptide. The blend has never been tested in a controlled trial, so any figure you see for a "KLOW dose" is unvalidated. What does exist is a widely listed research vial — the way the mixture is supplied for laboratory handling — and a set of doses from the single-component animal studies.

Those component doses cannot simply be added together. They were measured in different species, by different routes, for different peptides — micrograms per kilogram in one study, nanomolar in a dish in another. You cannot stack them into one number. This page describes what was administered in the research, never what a person should take. It contains no human dosing instruction, and the practical handling questions — where the component routes were studied, how the blend is reconstituted — sit on the component half-lives page.

The canonical research vial

The most widely listed research vial is 80 mg total: GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg and KPV 10 mg, co-dissolved at fixed mass ratios and reconstituted with bacteriostatic water for laboratory handling ^[4]. That is a vial composition for handling a research chemical — not a human dose, and not a recommendation. GHK-Cu accounts for about 62.5% of the vial mass; the other three arms split the rest in equal 10 mg shares.

No validated human dosing exists for the blend, and the component-level research doses differ widely by species and route. They are not additive into a single 'KLOW dose.' A figure that looks precise — "80 mg" — describes how the mixture is packaged, not how much of any arm reaches a target, which depends on route, clearance and the specific peptide.

Component research doses, by arm and route

Each arm's research doses belong to its own studies. KPV was effective at 10 nM in epithelial and immune cell culture and at 100 uM in the drinking water of colitis-model mice ^[3] — a cell-culture concentration and an oral animal exposure, not a human figure. GHK-Cu's quantitative human data are topical: a skin-penetration study delivered copper as GHK-Cu and measured a dermal depot of 97 ug/cm^2 over 48 hours ^[6], while the matrix effects were established at nanomolar concentrations in vitro and in topical clinical formulations ^[4].

BPC-157's rodent tendon work used 10 microg, 10 ng or 10 pg per rat by intraperitoneal injection ^[2]; its formal PK study spanned intravenous and intramuscular routes, reporting intramuscular bioavailability of roughly 14-19% in rats and 45-51% in dogs ^[7]. TB-500's foundational doses are for the full-length protein — the rat wound work used topical and intraperitoneal thymosin beta-4, with keratinocyte migration stimulated by as little as 10 pg ^[1]. Four arms, four sets of units, no common scale: that is precisely why no single blend dose can be assembled.

Frequently asked: dose and frequency

Three dose-and-frequency questions recur about KLOW peptide, and each has the same honest answer drawn from the same fact — the blend has never been studied in people. The three short answers below state that plainly, with the relevant component figures where they exist.

How much KLOW peptide per day?

No validated human per-day amount exists for the blend. The canonical research vial lists fixed component masses (GHK-Cu 50, BPC-157 10, TB-500 10, KPV 10 mg) for laboratory handling, not a daily human dose ^[4]. Component research doses are species- and route-specific and cannot be summed into one figure.

How often should you take KLOW peptide?

Frequency is not established for the blend in humans. The four peptides have markedly different reported half-lives — BPC-157 clears in under 30 minutes in the formal PK study, the tripeptides faster still ^[7] — so no single dosing cadence can match all four arms. Any schedule would suit at most one component.

What is the KLOW peptide dosage and frequency?

Neither dose nor frequency is established for the blend. The pharmacokinetic mismatch between the fast-clearing tripeptides (KPV, GHK-Cu) and the larger BPC-157 means no single schedule aligns all components at matched exposure ^[7]. The blend has never been tested in a controlled trial, so any combined figure is unvalidated.